Enzo Biochem, Inc. ($0.01 Par Value) (ENZ) News
Enzo Biochem, Inc. ($0.01 Par Value) (ENZ)
Today's Latest Price: $1.82 USD
Updated Oct 30 7:00pm
Add ENZ to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
Filter ENZ News Items
ENZ News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ENZ News From Around the Web
Below are the latest news stories about Enzo Biochem Inc that investors may wish to consider to help them evaluate ENZ as an investment opportunity.
Edited Transcript of ENZ earnings conference call or presentation 8-Jun-20 9:00pm GMTQ3 2020 Enzo Biochem Inc Earnings Call |
Enzo Biochem to provide COVID-19 testing at 50+ New York pharmaciesEnzo Biochem ([[ENZ]] -0.6%) partners with Community Pharmacy Enhanced Services Network, to provide COVID-19 testing at 52 of the network’s 155 pharmacies across New York State.The company will provide the full range of services, including reagent manufacturing capabilities, diagnostic instruments, and clinical laboratory services.... |
ENZO BIOCHEM TO PROVIDE ACCESS TO COVID-19 TESTING AT MORE THAN 50 NY PHARMACIES IN COLLABORATION WITH CPESN NYNEW YORK, NY, July 21, 2020 -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostic company, and Community Pharmacy Enhanced Services Network (CPESN® NY), the. |
Do Insiders Own Lots Of Shares In Enzo Biochem, Inc. (NYSE:ENZ)?The big shareholder groups in Enzo Biochem, Inc. (NYSE:ENZ) have power over the company. Institutions will often hold... |
Enzo Biochem shares rise on FDA authorization for coronavirus testShares of Enzo Biochem Inc. rallied 7.7% in premarket trading on Monday after the company said it received an emergency use authorization from the Food and Drug Administration for its COVID-19 diagnostic test. The regulator issued the EUA on July 7. It has granted emergency authorization to at least 137 diagnostic tests during the COVID-19 pandemic. Enzo's stock is up 8.7% year-to-date. The S&P 500 has declined 1.4% since the start of the year. |
Enzo Biochem Receives Emergency Use Authorization for Proprietary Test System for Detection of Coronavirus SARS-CoV-2Flexible Use on Three Platforms including Enzo’s Proprietary Automated GENFLEX™ Platform NEW YORK, NY, July 13, 2020 -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences. |
Enzo Biochem's COVID test granted emergency authorization from the FDAEnzo Biochem (ENZ) soared 21% yesterday as its Ampiprobe SARS-CoV-2 Test System was granted Emergency Use Authorization by the FDA in a letter.The letter stated, "based on the totality of scientific evidence available to FDA, it is reasonable to believe that your product may be effective in diagnosing COVID-19, and that... |
Enzo Biochem to Provide COVID-19 Testing to Farmingdale State College Staff and Students as They Return to CampusEnzo Biochem, Inc. (ENZ), a leading biosciences and diagnostic company, and Farmingdale State College today announced they are partnering to provide molecular and antibody testing for COVID-19 to the campus community as the college reopens this summer and begins classes in the fall. “This program fits perfectly into this fall’s campus plans designed by our COVID-19 Task Force, and testing our students with no required financial outlay is important,” said Farmingdale State College President John S. Nader. Testing by Enzo is a component of Farmingdale’s comprehensive fall campus plan, which also includes mandatory face coverings, social distancing, and delivery of classes through a combination of face-to-face, remote learning, and online instruction. |
Should You Avoid Enzo Biochem, Inc. (ENZ)?At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […] |
Enzo Announces Issuance of U.S. Patent for Methods of Treating Liver Cancer Using Proprietary Compound SK1-IEnzo Biochem, Inc. (ENZ), a leading biosciences and diagnostics company, today announced it has received a patent for the treatment of liver cancer, U.S. Patent No. 10,675,255 entitled Sphingosine Pathway Modulating Compounds for the Treatment of Cancers. Enzo’s patent is directed to methods for treating hepatocellular carcinoma (HCC), the most common human liver cancer, using the company’s proprietary compound SK1-I and has a term extending into June 2038. |
